TICKERNERD
Menu
VSTMVSTMHealthcare · Biotechnology

VSTM Stock Forecast: Verastem, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$7.32
−3.94% on the day

The 9 Wall Street analysts covering Verastem, Inc. hold a median 12-month price target of $15 — +104.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 10 Sept 2026 — in the upper half.

Market cap
$690.1M
Ticker Nerd rank
60 / 100
Median analyst target
$15
Analysts covering
9
Revenue$40.1M+1775.4% y/y
Operating income−$32.7M
Net income−$34.7M
Free cash flow−$43.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.3%
1M
+3.8%
YTD
−5.2%
1Y
−21.7%
From 52W high
−31.2%
From 52W low
+112.2%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VSTM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Verastem, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Volatility
78
Value
71
Accruals
57
Revisions
54
Size
50
Momentum
45
Quality
39
Issuance
34

Growth (89): Sales and profits are climbing, and climbing faster than before.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VSTM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VSTM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26VSTMHigh $18Median $15Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $11Median $15High $18

The green dot is the last close — the median target sits +104.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
11 Aug 2026MizuhoMaintainsOutperform$14 → $13
7 Aug 2026GuggenheimMaintainsBuy$14 → $12
7 July 2026RBC CapitalMaintainsOutperform$15 → $14
7 July 2026RBC CapitalMaintainsOutperform—
2 July 2026BTIGMaintainsBuy—
2 July 2026BTIGMaintainsBuy$18
24 June 2026BTIGReiteratesBuy—
24 June 2026HC Wainwright & Co.ReiteratesBuy—
23 June 2026JefferiesMaintainsBuy—
14 May 2026MizuhoMaintainsOutperform—
8 May 2026BTIGMaintainsBuy—
23 Apr 2026BTIGReiteratesBuy—
20 Apr 2026BTIGReiteratesBuy—
10 Apr 2026BTIGReiteratesBuy—
10 Apr 2026HC Wainwright & Co.ReiteratesBuy—
30 Mar 2026JefferiesAssumesBuy$19 → $15
12 Mar 2026BTIGAssumesBuy$19
4 Feb 2026HC Wainwright & Co.AssumesBuy$18
16 Oct 2025Cantor FitzgeraldAssumesOverweight—
9 Sept 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VSTM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VSTM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Verastem, Inc. returned −21.7% against +17.5% for the S&P 500, dividends included.

VSTM vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26VSTMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VSTM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Verastem, Inc. (VSTM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.5×

Cheaper than 86% of US stocks

Price / sales
7.9×

Cheaper than 17% of US stocks

Price / book
8.2×

Cheaper than 12% of US stocks

EV / EBITDA
−4.2×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
1775.4%

Higher than 99% of US stocks

Earnings growth (YoY)
1775.4%

Higher than 98% of US stocks

Gross margin
89.9%

Higher than 96% of US stocks

Operating margin
−81.6%

Higher than 15% of US stocks

Net margin
−231.6%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−471.2%

Higher than 3% of US stocks

Return on assets
−49.6%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Verastem, Inc. (VSTM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Verastem, Inc. has a market value of $690.1M and an enterprise value of $667.1M.

  • Revenue in the twelve months to 30 June 2026: $87.5M. The latest quarter grew 1775.4% year on year.

  • Net income over the same four quarters: −$202.7M, a −231.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$171.8M.

  • Shares outstanding: 90.5M.

  • Trailing P/E: −2.5×; forward P/E: −10.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Verastem, Inc. employs 102 people — $858K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

VSTM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VSTMVerastem, Inc.$690.1M
60
SGMTSagimet Biosciences, Inc.$676.7M
35
BLSMBlossomhill Therapeutics, Inc.$659.1M
1
MDXGMiMedx Group, Inc.$683.4M
75
PHATPhathom Pharmaceuticals, Inc.$655.3M
73
NGNENeurogene, Inc.$697.2M
60
ALTAltimmune, Inc.$639.4M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Verastem, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VSTM news & analysis

Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

Zacks Investment Research · 8 Sept 2026positive

Verastem shares surged 121% over three months, according to the report. The rise is attributed to commercial traction for its co-pack product and progress with its cancer drug candidate across key studies.

Why it matters — A VSTM watcher would care because the report points to growing commercial adoption and advancing clinical development as drivers behind the significant share price movement.

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Business Wire · 8 Sept 2026positive

Verastem Oncology announced it will host an investor event on October 14 at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375, an oral KRAS G12D inhibitor, in pancreatic, lung, and colorectal cancers from its ongoing TARGET-D clinical program.

Why it matters — The presentation of initial clinical data for VS-7375 across multiple cancer types provides a key update on a promising pipeline asset for Verastem Oncology watchers.

Verastem Oncology to Participate in Upcoming September Investor Conferences

Business Wire · 2 Sept 2026neutral

Verastem Oncology announced that its management team is scheduled to participate in upcoming September investor conferences, including the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston, and will present at the Cantor Global Healthcare Conference in New York City on September 10, as well as the H.C. Wainwright Annual Global Investment Conference.

Why it matters — For VSTM watchers, this signals the company's management will engage with investors and present at several major industry conferences this month.

Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform

Seeking Alpha · 31 Aug 2026positive

Verastem is transitioning from a speculative biotech into a commercially validated precision oncology company, using AVMAPKI FAKZYNJA revenue to fund its KRAS G12D programs. The launch has shown strong product-market fit with $43.7M in H1 2026 revenue and growing prescriber adoption, with an October 2026 VS-7375 data update cited as a pivotal catalyst.

Why it matters — A VSTM watcher would care because positive VS-7375 data could unlock multibillion-dollar KRAS G12D markets in pancreatic, lung, and colorectal cancer, while the AVMAPKI FAKZYNJA launch provides commercial validation and funding for the pipeline.

Verastem Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Verastem reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK. The company attributed the result to increased new patient starts, refills, and physician adoption, describing it as a rebound in commercial performance.

Why it matters — A VSTM watcher would care because the quarterly revenue figure and improved patient/physician trends signal the commercial momentum of its co-pack product.

FAQ

Frequently asked questions about VSTM stock

What is the VSTM stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Verastem, Inc. have a median 12-month price target of $15, with estimates ranging from $11 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VSTM stock a buy right now?

Of the 9 analysts covering Verastem, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Verastem, Inc. 60 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VSTM?

As at 10 Sept 2026, Verastem, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will VSTM stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +104.9% from the last close, and Ticker Nerd's factor model ranks Verastem, Inc. 60 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VSTM stock forecast for 2030?

No analyst covering Verastem, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VSTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $18 over the next 12 months.

How has VSTM stock performed over the past year?

Verastem, Inc. returned -21.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Verastem, Inc. do?

Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway.

What is the latest news on VSTM?

The most recent item we track (Zacks Investment Research, 8 Sept 2026): "Verastem Stock Skyrockets 121% in 3 Months: Here Is Why". Verastem shares surged 121% over three months, according to the report. The rise is attributed to commercial traction for its co-pack product and progress with its cancer drug candidate across key studies.

Company

About Verastem, Inc.

Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway. Verastem Oncology’s current portfolio includes marketed and investigational therapies designed to address difficult-to-treat cancers, including rare ovarian cancer and other solid tumors. The company’s product and pipeline programs center on small-molecule oncology treatments such as RAF/MEK and FAK pathway inhibitors, reflecting a targeted approach to tumor biology. Verastem also works with companion diagnostics and clinical collaborations to support patient selection and study combination regimens. Based in Needham, Massachusetts, Verastem serves the oncology market by advancing therapies intended to improve treatment options across specialized cancer indications.

CEO Mr. Daniel W. Paterson · 102 employees · United States · https://www.verastem.com